10.17843/rpmesp.2020.373.4787
ORIGINAL ARTICLE
Clinical-epidemiological analysis of HDL2 and HDL3 subfractions in adults from Maracaibo city, Venezuela
Sergia Linares
, Master in Nutrition, Master in Human Metabolism,
Doctor of Medical Sciences
Valmore Bermúdez
, Master in Human Metabolism, Doctor of Medical Sciences
Juan Salazar
, Medical Doctor, Specialist in Internal Medicine
Manuel Nava
, Student of Human
Medicine
Ãngel Ortega
, Student of Human
Medicine
Luis Olivar
, Student of Human
Medicine
María Calvo
, Student of Human
Medicine
María Sofía Martínez
, Medical
Doctor
Alex Morales-Carrasco
, Medical
Doctor
Maricarmen Chacón
, Master in
Dermatology
Joselyn Rojas
, Master in Immunology
ABSTRACT
Objective: To carry out a clinical-epidemiological analysis of high-density lipoprotein cholesterol subfractions (HDL-C) in adults from Maracaibo, Venezuela.
Materials and methods: A descriptive and cross-sectional study of the database from the Metbolic Syndrome Prevalence in Maracaibo Study was carried out. HDL3 and HDL2 serum concentration, as well as the HDL2/HDL3 ratio, were determined in 359 individuals of both sexes, over 18 years of age. Values obtained were evaluated according to sociodemographic, clinical and biochemical characteristics.
Results: Mean population age was 39.4 ± 15.2 years, and 51.5% were female. Differences in HDL-C subfraction levels were only observed in those subjects with low HDL-C levels. Women with hypertriglyceridemia showed significantly lower serum HDL3 and HDL2 concentrations than those with normal triglycerides (p=0.033), as well as a lower HDL3 level and HDL2 / HDL3 ratio in those with higher levels of ultra-sensitive C-reactive protein (us-CRP) (p<0.001). A significantly lower concentration of HDL2 was observed in men with some degree of hypertension (p=0.031), insulin resistance (p=0.050) and metabolic syndrome (p=0.003); while those with elevated us-CRP showed a lower concentration of HDL3 (p=0.011).
Conclusion: HDL-C subfractions show varying clinical-epidemiological behavior in adults from Maracaibo. Lower serum levels are observed in men, differences only in those with low HDL-C; and no predominance of any subclass was observed according to sociodemographic, clinical and biochemical characteristics.
Keywords: Lipoproteins, HDL3; Lipoproteins, HDL2; Cholesterol, HDL; Risk Factors; Epidemiology (source: MeSH NLM).
KEY MESSAGES |
Motivation for the study: The epidemiological behavior of HDL-C subfractions
and their relationship with other metabolic alterations in Latin American
populations, especially in Venezuela, is unknown. Main findings: The average of HDL-C subfractions was
lower in men; differences were only evident in subjects with low HDL-C. Subfractions had variable behavior and lower levels were
observed in men and women with clinical and metabolic disorders. Implications: HDL-C subfractions represent laboratory
parameters of potential utility in individuals with low HDL-C. Their
measurement in this context would allow early identification of subjects with
risk factors, especially in those with intermediate or low cardiovascular
risk |
The ethics committee of the Centro de Investigaciones Endocrino-Metabólicas
(CIEM) “Dr. Félix Gómez” of the Universidad del Zulia,
Venezuela, approved the study and authorized the use of the database for this
sub-analysis. All participants signed an informed consent form prior to any
intervention, interrogation, and physical examination.
Table 1. General characteristics of the studied population
Characteristics |
Women |
Men |
Total |
|||
(n = 185) |
(n = 174) |
(n = 359) |
||||
n |
% |
n |
% |
n |
% |
|
Age group (years) |
|
|
|
|
|
|
<30 |
54 |
29.2 |
67 |
38.5 |
121 |
33.7 |
30-49 |
71 |
38.4 |
63 |
36.2 |
134 |
37.3 |
≥50 |
60 |
32.4 |
44 |
25.3 |
104 |
29.0 |
Marital status |
|
|
|
|
|
|
Single |
95 |
51.4 |
82 |
47.1 |
177 |
49.3 |
Married |
90 |
48.6 |
92 |
52.9 |
182 |
50.7 |
Employment status |
|
|
|
|
|
|
Employed |
81 |
43.8 |
135 |
77.6 |
216 |
60.2 |
Unemployed |
104 |
56.2 |
39 |
22.4 |
143 |
39.8 |
Educational level |
|
|
|
|
|
|
Up to primary school |
38 |
20.5 |
20 |
11.5 |
58 |
16.2 |
Secondary |
78 |
42.2 |
88 |
50.6 |
166 |
46.2 |
Higher |
69 |
37.3 |
66 |
37.9 |
135 |
37.6 |
Socioeconomic stratum |
|
|
|
|
|
|
I-II |
34 |
18.4 |
35 |
20.1 |
69 |
19.2 |
III |
87 |
47.0 |
77 |
44.3 |
164 |
45.7 |
IV-V |
64 |
34.6 |
62 |
35.6 |
126 |
35.1 |
Race |
|
|
|
|
|
|
Mestizo |
141 |
76.6 |
134 |
77.0 |
275 |
76.8 |
White-Hispanic |
24 |
13.0 |
26 |
14.9 |
50 |
14.0 |
Afro-Venezuelan |
3 |
1.6 |
5 |
2.9 |
8 |
2.2 |
American Indian |
16 |
8.7 |
9 |
5.2 |
25 |
7.0 |
Alcohol consumption * |
|
|
|
|
|
|
Yes |
33 |
17.8 |
100 |
57.5 |
133 |
37,0 |
No |
152 |
82.2 |
74 |
42.5 |
226 |
63,0 |
Tobacco smoking habits |
|
|
|
|
|
|
No |
153 |
82.7 |
111 |
63.8 |
264 |
73.5 |
Smoker |
14 |
7.6 |
26 |
14.9 |
40 |
11.1 |
Ex-smoker |
18 |
9.7 |
37 |
21.3 |
55 |
15.3 |
Leisure physical activity |
|
|
|
|
|
|
None |
127 |
68.6 |
82 |
47.1 |
209 |
58.2 |
Extremely low |
7 |
3.8 |
19 |
10.9 |
26 |
7.2 |
Low |
19 |
10.3 |
15 |
8.6 |
34 |
9.5 |
Moderate |
11 |
5.9 |
21 |
12.1 |
32 |
8.9 |
High |
10 |
5.4 |
14 |
8.0 |
24 |
6.7 |
Extremely high |
11 |
5.9 |
23 |
13.2 |
34 |
9.5 |
Low HDL-C |
|
|
|
|
|
|
No |
86 |
46.5 |
84 |
48.3 |
170 |
47.4 |
Yes |
99 |
53.5 |
90 |
51.7 |
189 |
52.6 |
AF: actividad física
* Consumidor >1 g/día
Figure 1. Epidemiological behavior of HDL-C concentration and subfractions
according to sex
Table 2. Percentiles of HDL subfractions
in the population studied
Variable |
p25 |
p33.3 |
Median |
p66.6 |
p75 |
p95 |
Women (n = 185) |
|
|
|
|
|
|
HDL3 (mg/dL) |
19.9 |
22.7 |
26.7 |
33.1 |
36.9 |
49.8 |
HDL2 (mg/dL) |
10.7 |
13.0 |
17.6 |
20.8 |
24.6 |
36.0 |
HDL2/HDL3 |
0.35 |
0.43 |
0.66 |
0.86 |
1.02 |
1.89 |
Men (n = 174) |
|
|
|
|
|
|
HDL3 (mg/dL) |
18.9 |
21.0 |
24.8 |
28.9 |
30.5 |
42.2 |
HDL2 (mg/dL) |
9.2 |
10.9 |
13.8 |
16.1 |
18.1 |
33.6 |
HDL2/HDL3 |
0.35 |
0.41 |
0.56 |
0.74 |
0.83 |
2.47 |
p: percentile
Table 3. HDL subfractions according to sociodemographic characteristics
and habits in subjects with low HDL-C
SD: standard
deviation.
§Consumer >1 g/day.
*t-Student test to compare between two categories, or one-factor ANOVA test to
compare between three or more categories. In patients with normal HDL, no
significant differences were observed between group means.
Table 4. HDL Subfractions
according to clinical-metabolic characteristics and sex of subjects with low
HDL-C
TG: triacylglycerides; BMI:
body mass index; AC: abdominal circumference; IR: insulin resistance; us-CRP:
ultra-sensitive C-reactive protein; MS: metabolic syndrome.
† Criteria according to IDF/NHLBI/AHA consensus; ¶
Criteria according to EPSMM (HOMA2-IR≥2).
* t-Student test to compare between two categories, or
single-factor ANOVA test to compare between three or more categories in
patients with normal HDL; no significant differences between group means were
observed.
In conclusion, HDL-C subfractions
have variable clinical-epidemiological behavior in adult individuals of
Maracaibo’s population, lower averages in men, differences in socioeconomic
levels only in those with low HDL-C, and no predominance of any subclass
according to sociodemographic, clinical and biochemical characteristics.
Therefore, it is suggested to deepen the study of these lipoproteins in the
Latin American population, emphasizing their relationship with different
disorders that lead to a higher cardiometabolic risk.
REFERENCES
1. Besler C, Lüscher T, Landmesser U. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Molecular Medicine. 2012;4(4):251-268. doi: 10.1002/emmm.201200224.
2. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–88. doi: 10.1016/S0140-6736(18)32203-77 .
3. Bermudez V, Salazar J, Rojas J, Martínez MS, Bello L, Añez R, et al. Prevalence, Lipid Abnormalities Combinations and Risk Factors Associated with Low HDL-C Levels in Maracaibo City, Venezuela. J J Commun Med. 2015;1(2):009.
4. Bermúdez V, Salazar J, Bello L, Rojas J, Añez R, Roque W, et al. Coronary Risk Estimation According to a Recalibrated Framingham-Wilson Score in the Maracaibo City Metabolic Syndrome Prevalence Study. The Journal for Cardiology. Photon 2014;107:160-170.
5. Salazar J, Cabrera M, Ramos E, Olivar L, Aguirre M, Rojas J, et al. HDL-C y riesgo de aterosclerosis. Diabetes Internacional. 2013;5(2):42-54.
6. Salazar J, Olivar LC, Ramos E, Chávez-Castillo M, Rojas J, Bermudez V. Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics. Cholesterol. 2015;2015:296417. doi: 10.1155/2015/296417.
7. Martin S, Jones S, Toth P. High-density lipoprotein subfractions: current views and clinical practice applications. Trends Endocrinol Metab. 2014;25(7):329-36. doi: 10.1016/j.tem.2014.05.005.
8. De Lalla OF, Gofman JW. Ultracentrifugal analysis of serum lipoproteins. Methods Biochem Anal. 1954;1:459-478. doi: 10.1002/9780470110171.ch16.
9. Pirillo A, Norata G, Catapano A. High-Density Lipoprotein Subfractions - What the Clinicians Need to Know. Cardiology. 2013;124(2):116-125. doi: 10.1159/000346463.
10. Davidson M. The Battle of the HDL Subfractions. Cardiovasc Revasc Med. 2019;20(11):943-944. doi: 10.1016/j.carrev.2019.09.013.
11. Bermúdez V, Marcano R, Cano C, Arráiz N, Amell A, Cabrera M, et al. The Maracaibo City Metabolic Syndrome Prevalence Study: Design and Scope . Am J Ther. 2010;17(3):288-294. doi: 10.1097/MJT.0b013e3181c121bc.
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003;289:2560-2571. doi: 10.1161/01.HYP.0000107251.49515.c2.
13. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser [Internet]. WHO; 2000 [citado el 01 de agosto de 2019]. Disponible en: https://www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/ .
14. Alberti K, Eckecl R, Grundy S, Zimmer PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention: National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Circulation. 2009;120:1640-45. doi: 10.1161/CIRCULATIONAHA.109.192644.
15. Bermúdez V, Cabrera M, Mendoza L, Chávez M, Martínez M, Rojas J, et al. High-sensitivity c-reactive protein epidemiological behavior in adult individuals from Maracaibo, Venezuela. Revista Latinoamericana de Hipertensión. 2013;8(1):22-29.
16. Bermúdez V, Rojas J, Salazar J, Bello L, Áñez R, Toledo A, et al. Variations of Lipoprotein(a) Levels in the Metabolic Syndrome: A Report from the Maracaibo City Metabolic Syndrome Prevalence Study. J Diabetes Res. 2013;2013:416451. doi: 10.1155/2013/416451.
17. Bermúdez V, Rojas J, Martínez M, Apruzzese V, Chávez-Castillo M, Gonzalez R, et al. Epidemiologic Behavior and Estimation of an Optimal Cut-Off Point for Homeostasis Model Assessment-2 Insulin Resistance: A Report from a Venezuelan Population. Int Sch Res Notices. 2014;2014:616271. doi: 10.1155/2014/616271.
18. Williams P. Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman’s Livermore Cohort. J Lipid Res. 2012;53(2):266-272. doi: 10.1194/jlr.M019356.
19. Chaudhary R, Kinderytė M, Chaudhary R, Sukhi A, Bliden K, Tantry U, et al. HDL3-C is A Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy. Cardiovasc Revasc Med. 2019;20:1001-6. doi: 10.1016/j.carrev.2018.12.019.
20. Bermudez V, Rojas J, Salazar J, Calvo MJ, Morillo J, Torres W, et al. The Maracaibo city metabolic syndrome prevalence study: primary results and agreement level of 3 diagnostic criteria. Revista Latinoamericana de Hipertensión. 2014;9(4):20-31.
21. Souki A, Sandoval M, Sánchez G, Andrade U, García-Rondón D, Cano C, et al. Intake of saturated fatty acids and sensitivity to insulin in obese young adults in Maracaibo. Revista Latinoamericana de Hipertensión. 2007;3(5):159-165.
22. Kim DS, Burt AA, Rosenthal EA, Ranchalis JE, Eintracht JF, Hatsukami TS, et al. HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J Am Heart Assoc. 2014;3(3):e000902. doi: 10.1161/JAHA.114.000902.
23. Koumaré AT, Sakandé LP, Kabré E, Sondé I, Simporé J, Sakandé J. Reference ranges of cholesterol sub-fractions in random healthy adults in Ouagadougou, Burkina Faso. PLoS One. 2015;10(1):e011642. doi: 10.1371/journal.pone.0116420..
24. Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. Eur Heart J. 2015;36(1):22-30. doi: 10.1093/eurheartj/ehu264.
25. Quintanilla-Cantú A, Peña-de-la-Sancha P, Flores-Castillo C, Mejía-Domínguez AM, Posadas-Sánchez R, Pérez-Hernández N, et al. Small HDL subclasses become cholesterol-poor during postprandial period after a fat diet intake in subjects with high triglyceridemia increases. Clin Chim Acta. 2017;464:98-105. doi: 10.1016/j.cca.2016.11.018.
26. Jia L, Fu M, Tian Y, Xu Y, Gou L, Tian H, et al. Alterations of high-density lipoprotein subclasses in hypercholesterolemia and combined hyperlipidemia. Int J Cardiol. 2007;120(3):331-7. doi: 10.1016/j.ijcard.2006.10.007.
27. Generoso G, Bensenor IM, Santos RD, Santos IS, Goulart AC, Jones SR, et al. Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. J Clin Lipidol. 2018;12(5):1290-1297. doi: 10.1016/j.jacl.2018.05.003.
28. Cartolano FDC, Dias GD, Freitas MCP de, Figueiredo Neto AM, Damasceno NRT. Insulin Resistance Predicts Atherogenic Lipoprotein Profile in Nondiabetic Subjects. J Diabetes Res. 2017;2017:1018796. doi: 10.1155/2017/1018796.
29. Jo N, Garmendia F, Pando R. Sub-clases de lipoproteínas de alta densidad en diabéticos. Rev méd peru.1994;66(351):68-70.
30. Moriyama K, Takahashi E. HDL2/HDL3 ratio changes, metabolic syndrome markers, and other factors in a Japanese population. J Atheroscler Thromb. 2016;23(6):704-712. doi: 10.5551/jat.32896.
Correspondence to: Juan Salazar; Centro de Investigaciones Endocrino-Metabólicas «Dr. Félix Gómez», Escuela de Medicina, Universidad del Zulia. Maracaibo 4004, Venezuela; juanjsv18@hotmail.com.
Sources of funding: This study was funded by the Consejo de Desarrollo Científico, Humanístico y Tecnológico CONDES
(CC-0437-10-21-09-10) and by Fundacite-Zulia
(FZ-0058- 2007).
Cite as: Linares S,
Bermúdez V, Salazar J, Nava M, Ortega A, Olivar L, et al. Clinical-epidemiological analysis
of hdl2 and hdl3 subfractions in adults from
Maracaibo city, Venezuela. Rev Peru Med Exp Salud Publica. 2020;37(3). doi:
https://doi.org/10.17843/rpmesp.2020.373.4787.